1. A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Issue 5 (2nd July 2018) Authors: El Sharkawy, R.; Thabet, K.; Lampertico, P.; Petta, S.; Mangia, A.; Berg, T.; Metwally, M.; Bayoumi, A.; Boonstra, A.; Brouwer, W. P.; Smedile, A.; Abate, M. L.; Loglio, A.; Douglas, M. W.; Khan, A.; Santoro, R.; Fischer, J.; Leeming, D. J.; Liddle, C.; George, J. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 5(2018) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. Issue 1 (February 2018) Authors: Loglio, A.; Galmozzi, E.; Iavarone, M.; Grossi, G.; Viganò, M.; Facchetti, F.; Perbellini, R.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients. (February 2020) Authors: Viganò, M.; Loglio, A.; Cerini, F.; Farina, E.; Facchetti, F.; Perbellini, R.; Rumi, M.G.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long‐term analogue therapy for hepatitis B. Issue 4 (19th June 2018) Authors: Loglio, A.; Iavarone, M.; Grossi, G.; Viganò, M.; Rumi, MG.; Facchetti, F.; Lunghi, G.; Sangiovanni, A.; Colombo, M.; Lampertico, P. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 4(2018) Page Start: 431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis. (February 2019) Authors: Loglio, A.; Alexandrov, A.; Renteria, S.C. Uceda; Tham, C.Y.L.; Greco, L.; Borghi, M.; Perbellini, R.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Lecchi, L.; Prati, D.; Ceriotti, F.; Lunghi, G.; Bertoletti, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients. Issue 1 (16th February 2017) Authors: Viganò, M.; Grossi, G.; Loglio, A.; Cappelletti, M.; Zaltron, S.; Castelli, F.; Andreone, P.; Messina, V.; Ganga, R.; Coppola, N.; Marrone, A.; Russello, M.; Marzano, A.; Taliani, G.; Fasano, M.; Fagiuoli, S.; Villa, E.; Bronte, F.; Santantonio, T.; Brancaccio, G. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. Issue 1 (February 2018) Authors: Iavarone, M.; Loglio, A.; Grossi, G.; Viganò, M.; Facchetti, F.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Excellent long-term virological and clinical response in HDV compensated cirrhotics treated with high dose Bulevirtide beyond 2.5 years: A case series. (March 2021) Authors: Loglio, A.; Ferenci, P.; Renteria, SC. Uceda; Holzmann, H.; Borghi, M.; Perbellini, R.; Rimondi, A.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Prati, D.; Ceriotti, F.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di). (March 2023) Authors: Anolli, M.P.; Degasperi, E.; D'Offizi, G.; Brunetto, M.R.; Verucchi, G.; Federico, A.; Ciancio, A.; Mangia, A.; Santantonio, T.A.; Coppola, N.; Pellicelli, A.; Loglio, A.; Viganò, M.; Pileri, F.; Maracci, Monia; Puoti, M.; Piscaglia, F.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated hbv cirrhotics treated with nuc for 10 years. (February 2020) Authors: Galmozzi, E.; Loglio, A.; Facchetti, F.; Iavarone, M.; Borghi, M.; Viganò, M.; Perbellini, R.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗